Atara Biotherapeutics, Inc. key statistics and ratios

In fiscal 2025, Atara Biotherapeutics, Inc. had an operating margin of 29.7% and a current ratio of 0.82. Each ratio below is calculated from the figures on its income statement, balance sheet and cash flow pages.

Financial ratios

US$ thousands unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Atara Biotherapeutics, Inc.: financial ratios, annual
Fiscal year	2022Dec 2022	2023Dec 2023	2024Dec 2024	2025Dec 2025	LTMJun 2026
Operating margin	−441.2%	<−999%	−64.7%	29.7%	−229.7%
Net margin	−359.1%	<−999%	−66.2%	27.1%	−269.4%
Free-cash-flow margin	−432.0%	<−999%	−53.5%	−42.2%	−353.5%
Return on equity	−180.3%	—	—	—	—
Return on assets	−60.7%	−101.9%	−62.2%	50.5%	−80.9%
Asset turnover	0.17	0.03	0.94	1.87	0.30
Current ratio	3.74	0.72	0.48	0.82	1.98
Debt to equity	0.0%	0.0%	—	—	—
Interest cover (operating income ÷ interest)	n/m	n/m	n/m	9.5x	n/m
Effective tax rate	—	—	—	0.1%	—
R&D as % of revenue	428.7%	>999%	117.5%	31.0%	68.0%
Capital spending as % of revenue	6.6%	14.3%	0.2%	0.0%	0.0%
Free cash flow ÷ net income	—	—	—	−155.8%	—

US$ thousands unless shown otherwise. Fiscal quarters.

Atara Biotherapeutics, Inc.: financial ratios, quarterly
Quarter	2024 Q3Sept 2024	2024 Q4Dec 2024	2025 Q1Mar 2025	2025 Q2Jun 2025	2025 Q3Sept 2025	2025 Q4Dec 2025	2026 Q1Mar 2026	2026 Q2Jun 2026
Operating margin	−54.1%	−37.3%	39.5%	18.2%	−103.5%	−160.7%	−652.9%	−749.2%
Net margin	−54.5%	−38.8%	38.7%	13.6%	−124.6%	−213.5%	−803.3%	−767.3%
Free-cash-flow margin	−9.9%	−75.0%	−28.7%	−41.6%	−283.4%	−357.2%	—	−529.8%
Current ratio	0.59	0.48	0.57	1.70	1.02	0.82	2.16	1.98
R&D as % of revenue	109.3%	87.7%	28.0%	41.6%	84.7%	−14.0%	31.8%	213.5%

Returns use average equity or assets over the year. Return on equity is left blank when equity is negative or so small that the ratio says nothing (above ±200%); interest cover is left blank above 200 times. Price-based ratios such as P/E are on the valuation page.

Financial health

1 of 3 checks passed · June 30, 2026

What it owns · $21m

Short-term assets $14mLonger-term assets $7m

What it owes, and who funded it · $58m

Short-term liabilities $7mLonger-term liabilities $51mShareholders' equity $-37m

Short-term assets cover short-term liabilities $14m of assets due within a year against $7m of liabilities due within a year.
Short-term assets cover long-term liabilities $14m short-term assets against $51m of longer-dated liabilities.
More cash than debt Cash or debt not separately reported. Not assessable.
Debt below 40% of shareholders' equity Equity or debt not reported. Not assessable.
Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
A year's operating cash flow covers at least 20% of debt Cash flow or debt not reported. Not assessable.
Operating profit covers interest at least five times over Operating income of −$14m against $3m of interest.

From Atara Biotherapeutics, Inc.'s latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Moat

Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Medium.

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Compare with peers

Head to head: ATRA vs CGON ATRA vs FATE ATRA vs HCWB

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Atara Biotherapeutics, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Atara Biotherapeutics, Inc.